Private Advisor Group LLC Sells 1,053 Shares of DaVita Inc. (NYSE:DVA)

Private Advisor Group LLC lowered its stake in shares of DaVita Inc. (NYSE:DVA) by 46.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,223 shares of the company’s stock after selling 1,053 shares during the period. Private Advisor Group LLC’s holdings in DaVita were worth $200,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. SG Americas Securities LLC raised its position in shares of DaVita by 196.9% during the first quarter. SG Americas Securities LLC now owns 29,733 shares of the company’s stock valued at $4,105,000 after buying an additional 19,719 shares during the last quarter. Bessemer Group Inc. grew its holdings in shares of DaVita by 2,335.6% in the first quarter. Bessemer Group Inc. now owns 10,741 shares of the company’s stock valued at $1,483,000 after purchasing an additional 10,300 shares in the last quarter. Forsta AP Fonden grew its holdings in shares of DaVita by 50.3% in the first quarter. Forsta AP Fonden now owns 23,600 shares of the company’s stock valued at $3,258,000 after purchasing an additional 7,900 shares in the last quarter. Sei Investments Co. grew its holdings in shares of DaVita by 21.3% in the first quarter. Sei Investments Co. now owns 41,952 shares of the company’s stock valued at $5,790,000 after purchasing an additional 7,371 shares in the last quarter. Finally, BOKF NA grew its holdings in shares of DaVita by 286,550.0% in the first quarter. BOKF NA now owns 5,733 shares of the company’s stock valued at $790,000 after purchasing an additional 5,731 shares in the last quarter. Institutional investors own 90.12% of the company’s stock.

DaVita Stock Down 0.5 %

NYSE DVA opened at $149.65 on Friday. The company has a quick ratio of 1.33, a current ratio of 1.37 and a debt-to-equity ratio of 15.78. The company has a fifty day moving average of $157.15 and a two-hundred day moving average of $146.71. The firm has a market capitalization of $12.27 billion, a price-to-earnings ratio of 16.14, a PEG ratio of 0.83 and a beta of 0.89. DaVita Inc. has a 52 week low of $82.79 and a 52 week high of $168.50.

DaVita (NYSE:DVA) last issued its earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). The company had revenue of $3.26 billion for the quarter, compared to analysts’ expectations of $3.25 billion. DaVita had a net margin of 6.53% and a return on equity of 88.18%. The firm’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.85 earnings per share. On average, analysts predict that DaVita Inc. will post 9.71 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Barclays raised their target price on shares of DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. Truist Financial raised their target price on shares of DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a report on Monday, October 7th. UBS Group raised their target price on shares of DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a report on Thursday, August 8th. TD Cowen lifted their price objective on shares of DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a research note on Wednesday, July 24th. Finally, Bank of America lifted their price objective on shares of DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a research note on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $161.80.

Insider Activity

In other news, insider Kathleen Alyce Waters sold 7,857 shares of the business’s stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the completion of the sale, the insider now directly owns 83,011 shares of the company’s stock, valued at approximately $12,137,038.31. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, COO Michael David Staffieri sold 9,539 shares of DaVita stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $150.03, for a total value of $1,431,136.17. Following the completion of the sale, the chief operating officer now directly owns 241,945 shares in the company, valued at $36,299,008.35. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Kathleen Alyce Waters sold 7,857 shares of DaVita stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total value of $1,148,771.97. Following the completion of the sale, the insider now owns 83,011 shares of the company’s stock, valued at $12,137,038.31. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 173,482 shares of company stock valued at $27,387,069. 2.00% of the stock is currently owned by company insiders.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.